COMPANY
Jazz Pharmaceuticals
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Executive Assistant | 2 locations, including CA, Home Based, US | Oct 22, 2026 | Oct 23, 2026 |
| Associate Scientist (12 Month FTC) | Kent, United Kingdom | Oct 21, 2026 | Oct 21, 2026 |
| R&D Project Finance Manager | 2 locations, including Home Based, UK | Oct 21, 2026 | Oct 21, 2026 |
| Access & Reimbursement Manager, Sleep | 5 locations, including KY, Home Based, US | Oct 21, 2026 | Oct 22, 2026 |
| Senior Manager, Clinical Trial Finance Management | 2 locations, including Home Based, UK | Oct 21, 2026 | Oct 22, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 2/3 trial (NCT07723963, actual start Sep 18, 2026); 6 clinical-operations roles open. ClinicalTrials.gov NCT07723963 (Sep 18, 2026)
Evidence (1 event)
- Sep 18, 2026 · ClinicalTrials.gov NCT07723963
leadSponsor.name='Jazz Pharmaceuticals'; phases=['PHASE2', 'PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-18,type:ACTUAL}; studyFirstPostDate=2026-07-23; briefTitle='A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy'
- Sep 18, 2026 · ClinicalTrials.gov NCT07723963
Timeline
- Trial start Phase 2: A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC source ↗
- Trial start Phase 4: A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS source ↗
- Trial start Phase 3: A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE source ↗
- Trial start —: Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA source ↗
- Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants source ↗
- Trial start Phase 2/Phase 3: A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy source ↗
- Debt Debt: $1.1B (not counted as a raise), announced Aug 27, 2026. Source: SEC filing. source ↗
- Trial start Phase 2: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma source ↗
- Trial start Phase 3: A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH source ↗
- Trial start Phase 1: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants source ↗
- Trial start Phase 2: Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma source ↗
- Trial start Phase 1: A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures source ↗
- Trial start 2: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer source ↗
- Trial start —: Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy source ↗
- Trial start Phase 1: A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 source ↗
- Trial start —: Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY source ↗
- Trial start 2: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors source ↗
- Trial start Phase 3: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-posit source ↗
- Trial start Phase 3: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer source ↗
- Trial start —: VYxeoS Liposomal Italian Observational Study iN the Real Practice source ↗
- Trial start Phase 1: JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors source ↗
- Trial start Phase 4: A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy source ↗
- Trial start Phase 4: A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex source ↗
- Trial start Phase 4: A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy source ↗
- Trial start Phase 1/Phase 2: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma source ↗
Upcoming milestones
- Dec 31, 2026 (ESTIMATED) · 2 · A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors · NCT06695845
- 2027-02 (ESTIMATED) · · Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY · NCT05485831
- Feb 27, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants · NCT07813663
- Aug 1, 2027 (ESTIMATED) · Phase 4 · Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution · NCT05044819
- Nov 29, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures · NCT07233239
- Nov 30, 2027 (ESTIMATED) · Phase 1 · JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors · NCT06108050
- Dec 23, 2027 (ESTIMATED) · Phase 3 · A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH · NCT07625280
- Jan 1, 2028 (ESTIMATED) · 2 · A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · NCT07102381
Funding
- Debt: $1.1B (not counted as a raise), announced Aug 27, 2026. Source: SEC filing. source ↗
Clinical trials (lead sponsor) Showing 50 of 206
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07625280 | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH | Phase 3 | Recruiting | Jul 9, 2026 | Dec 23, 2027 (estimated) |
| NCT07723963 | A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy | Phase 2/Phase 3 | Recruiting | Sep 18, 2026 | Aug 1, 2028 (estimated) |
| NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase 2 | Recruiting | Jan 2, 2026 | Dec 15, 2028 (estimated) |
| NCT07780968 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA | Not listed | Not yet recruiting | Oct 1, 2026 | Oct 1, 2031 (estimated) |
| NCT06113237 | Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy | Not listed | Recruiting | Aug 5, 2025 | Aug 31, 2033 (estimated) |
| NCT07233239 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | Phase 1 | Recruiting | Nov 26, 2025 | Nov 29, 2027 (estimated) |
| NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | 2 | Recruiting | Sep 24, 2025 | Jan 1, 2028 (estimated) |
| NCT07728097 | A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS | Phase 4 | Not yet recruiting | Nov 18, 2026 | Dec 28, 2028 (estimated) |
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Phase 3 | Active, not recruiting | Dec 2, 2021 | Jul 15, 2026 (actual) |
| NCT04224272 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant | 2 | Completed | Jun 10, 2020 | Apr 28, 2023 (actual) |
| NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | Phase 2 | Recruiting | Nov 30, 2026 | Jan 31, 2028 (estimated) |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Recruiting | Jul 19, 2024 | Dec 1, 2028 (estimated) |
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Active, not recruiting | Oct 10, 2022 | Apr 1, 2028 (estimated) |
| NCT07813663 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants | Phase 1 | Not yet recruiting | Sep 22, 2026 | Feb 27, 2027 (estimated) |
| NCT05875974 | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy | Phase 4 | Completed | Jul 27, 2023 | Mar 13, 2025 (actual) |
| NCT05044819 | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | Phase 4 | Active, not recruiting | Jul 7, 2021 | Aug 1, 2027 (estimated) |
| NCT07533942 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | Phase 2 | Recruiting | Jul 16, 2026 | Oct 25, 2028 (estimated) |
| NCT07723976 | A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE | Phase 3 | Not yet recruiting | Oct 30, 2026 | Sep 4, 2029 (estimated) |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | 2 | Recruiting | Jan 14, 2025 | Dec 31, 2026 (estimated) |
| NCT05027139 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | Phase 1/Phase 2 | Completed | Sep 15, 2021 | Aug 29, 2025 (actual) |
| NCT05772429 | Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting | Not listed | Active, not recruiting | Apr 17, 2023 | 2026-07 (estimated) |
| NCT05485831 | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY | Not listed | Active, not recruiting | Feb 24, 2025 | 2027-02 (estimated) |
| NCT05864846 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex | Phase 4 | Completed | Jun 29, 2023 | Apr 6, 2026 (actual) |
| NCT05869773 | A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy | Phase 4 | Completed | Jun 26, 2023 | Feb 25, 2025 (actual) |
| NCT07377539 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants | Phase 1 | Recruiting | Feb 3, 2026 | Jul 5, 2026 (estimated) |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Recruiting | Jan 23, 2023 | 2028-06 (estimated) |
| NCT06961266 | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 | Phase 1 | Terminated | May 13, 2025 | Jan 29, 2026 (actual) |
| NCT04894591 | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) | Not listed | Completed | Jun 28, 2021 | Jun 4, 2025 (actual) |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Recruiting | Aug 13, 2024 | Apr 28, 2028 (estimated) |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/Phase 2 | Recruiting | May 23, 2023 | Jan 28, 2028 (estimated) |
| NCT05642442 | A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease | Phase 2 | Completed | Dec 1, 2022 | Oct 23, 2024 (actual) |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | I | Recruiting | Oct 26, 2020 | 2026-07 (estimated) |
| NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Recruiting | Nov 7, 2023 | Nov 30, 2027 (estimated) |
| NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice | Not listed | Completed | Dec 7, 2023 | Oct 23, 2025 (actual) |
| NCT04485104 | Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | Phase 3 | Terminated | May 19, 2021 | Jan 28, 2025 (actual) |
| NCT04466891 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | Phase 2 | Completed | Oct 1, 2020 | Jul 28, 2023 (actual) |
| NCT03929666 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | Phase 2 | Completed | Aug 29, 2019 | Aug 30, 2025 (actual) |
| NCT04617002 | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas | Not listed | Approved for marketing | Not listed | Not listed |
| NCT03295396 | ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | Phase 2 | Terminated | Oct 30, 2017 | Dec 31, 2022 (actual) |
| NCT05122650 | A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) | Phase 2 | Completed | Dec 6, 2021 | May 30, 2024 (actual) |
| NCT04578444 | An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer | Not listed | No longer available | Not listed | Not listed |
| NCT04745026 | Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | Phase 2 | Completed | May 31, 2021 | Dec 21, 2023 (actual) |
| NCT05126433 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors | Phase 2 | Terminated | Mar 3, 2022 | Dec 20, 2023 (actual) |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | Phase 1 | Terminated | Jan 25, 2018 | Dec 31, 2022 (actual) |
| NCT05288283 | Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures | Phase 3 | Terminated | Oct 31, 2022 | Sep 28, 2023 (actual) |
| NCT05178316 | A Study of JZP150 in Adults With Posttraumatic Stress Disorder | Phase 2 | Completed | Dec 29, 2021 | Dec 5, 2023 (actual) |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | Phase 2 | Terminated | 2016-01 | Apr 17, 2023 (actual) |
| NCT03485729 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Phase 2 | Terminated | Mar 21, 2018 | Jan 19, 2023 (actual) |
| NCT04984278 | Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis | Phase 3 | Terminated | Aug 16, 2021 | Nov 11, 2022 (actual) |
| NCT02892123 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Phase 1 | Completed | Sep 30, 2016 | Oct 31, 2024 (actual) |
Open jobs 49
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Executive Assistant | 2 locations, including CA, Home Based, US | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Associate Scientist (12 Month FTC) | Kent, United Kingdom | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| R&D Project Finance Manager | 2 locations, including Home Based, UK | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Access & Reimbursement Manager, Sleep | 5 locations, including KY, Home Based, US | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Senior Manager, Clinical Trial Finance Management | 2 locations, including Home Based, UK | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Senior Manager, Global Pricing & Access | 3 locations (listed on the posting) | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Portfolio Key Account Partner - New South Wales | Australia - Home-Based | Oct 20, 2026 | Oct 16, 2026 | Not stated |
| Senior Oncology Account Manager, Omaha | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Oncology Pharmacology | 4 locations, including Home Based, US | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Scientist, Quality Control (12 Month FTC) | Kent, United Kingdom | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Manager, Financial Planning & Performance Delivery | Ireland - Home-Based | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| Senior Director Customer Analytics & Insights EMD | US - Home-Based | Oct 14, 2026 | Oct 16, 2026 | Not stated |
| Senior Oncology Account Manager, Hematology - Phoenix | 3 locations (listed on the posting) | Oct 14, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Office of the CEO | 3 locations, including PA, Home Based, US | Oct 9, 2026 | Oct 16, 2026 | Not stated |
| Director, CX Advanced Analytics & AI Technical Suite Lead | 2 locations, including PA, Home Based, US | Oct 9, 2026 | Oct 16, 2026 | Not stated |
| Director, Compliance Business Partner | 2 locations, including PA, Home Based, US | Oct 8, 2026 | Oct 16, 2026 | Not stated |
| Director, US Commercial Forecasting & Analytics | US - Home-Based - PA | Oct 8, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Commercial Advanced Analytics | US - Home-Based | Oct 7, 2026 | Oct 16, 2026 | Not stated |
| Medical Director, GI Oncology and Solid Tumors | 2 locations (listed on the posting) | Oct 7, 2026 | Oct 16, 2026 | Not stated |
| Senior Principal Statistician, Biostatistics | 4 locations, including Home Based, UK | Oct 6, 2026 | Oct 16, 2026 | Not stated |
| Director, Global Commercial Finance Business Partner | US - Home-Based - PA | Oct 6, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, REMS Operations | US - Home-Based | Oct 2, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Central Monitoring | 3 locations (listed on the posting) | Oct 1, 2026 | Oct 16, 2026 | Not stated |
| Senior Clinical Trial Manager | Philadelphia, Pennsylvania | Oct 1, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, DEC Supply Chain Capability Lead (Remote/Home Based) | Ireland - Home-Based | Sep 30, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, AI Development Lead | US - Home-Based - MA | Sep 29, 2026 | Oct 16, 2026 | Not stated |
| Senior Oncology Account Manager, Hematology - Los Angeles | Los Angeles, California | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Director Toxicology | 3 locations, including Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Epidemiology | 3 locations (listed on the posting) | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Biostatistics | 3 locations (listed on the posting) | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Director, Taxation | 2 locations, including PA, Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Director, Real World Evidence | US - Home-Based | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Research Laboratory Operations | US - Site-Based - Durham | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Accountant, Statutory Financial Reporting (18 Month Fixed Term Contract - Remote / Home Based) | Ireland - Home-Based | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Financial Planning Excellence & Governance, 12 month FTC | 2 locations, including Home Based, Ireland | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Executive Director, Assistant General Counsel, Intellectual Property | 2 locations, including PA, Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Director, Sr. Corporate Counsel, IP | 2 locations, including PA, Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Automation Engineer | Ireland - Site-Based - Athlone | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Manager Advanced Analytics | US - Home-Based - PA | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Medical Director, Clinical Development, Oncology (Remote) | 3 locations, including PA, Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Market Access & Patient Support Services- Tech Lead | US - Home-Based - PA | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Enterprise AI Architect | US - Home-Based - PA | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, KOL & External Engagement Platforms Technical Lead | US - Home-Based - PA | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Sr Medical Science Liaison | Boston, Massachusetts | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Specialty Sales Consultant, Charleston SC | Charleston, South Carolina | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Senior Compliance Officer, Global R&D and Tech Ops | 2 locations, including PA, Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Principal, Data Engineering (Remote) | Philadelphia, Pennsylvania | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Specialty Sales Consultant Iowa (Remote) | 2 locations, including IA, Home Based, US | Sep 23, 2026 | Oct 16, 2026 | Not stated |
| Medical Science Liaison, Hematology - Northeast | 7 locations, including MA, Home Based, US | Sep 22, 2026 | Oct 16, 2026 | Not stated |
Connect
See your connections at Jazz Pharmaceuticals on LinkedIn (search by name, results not checked)